Enanta Pharmaceuticals Inc (ENTA)
9.31
+0.23
(+2.53%)
USD |
NASDAQ |
Nov 21, 16:00
9.30
-0.01
(-0.11%)
After-Hours: 20:00
Enanta Pharmaceuticals Enterprise Value: -32.82M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -32.82M |
| November 20, 2024 | -37.69M |
| November 19, 2024 | -30.49M |
| November 18, 2024 | -27.31M |
| November 15, 2024 | -28.16M |
| November 14, 2024 | -15.44M |
| November 13, 2024 | -9.088M |
| November 12, 2024 | -4.214M |
| November 11, 2024 | 0.2351M |
| November 08, 2024 | 4.473M |
| November 07, 2024 | 10.41M |
| November 06, 2024 | 14.01M |
| November 05, 2024 | 8.499M |
| November 04, 2024 | 5.320M |
| November 01, 2024 | 1.930M |
| October 31, 2024 | 8.181M |
| October 30, 2024 | 13.37M |
| October 29, 2024 | 13.58M |
| October 28, 2024 | 15.28M |
| October 25, 2024 | 17.40M |
| October 24, 2024 | 27.36M |
| October 23, 2024 | 40.07M |
| October 22, 2024 | 45.37M |
| October 21, 2024 | 37.74M |
| October 18, 2024 | 37.53M |
| Date | Value |
|---|---|
| October 17, 2024 | 30.11M |
| October 16, 2024 | 26.30M |
| October 15, 2024 | 17.19M |
| October 14, 2024 | 9.558M |
| October 11, 2024 | 3.837M |
| October 10, 2024 | -4.850M |
| October 09, 2024 | -3.155M |
| October 08, 2024 | 2.990M |
| October 07, 2024 | 14.64M |
| October 04, 2024 | 11.68M |
| October 03, 2024 | 7.015M |
| October 02, 2024 | 8.287M |
| October 01, 2024 | 1.718M |
| September 30, 2024 | -10.57M |
| September 27, 2024 | -17.14M |
| September 26, 2024 | -8.240M |
| September 25, 2024 | -4.003M |
| September 24, 2024 | 0.8707M |
| September 23, 2024 | 2.990M |
| September 20, 2024 | 8.922M |
| September 19, 2024 | 9.346M |
| September 18, 2024 | 11.25M |
| September 17, 2024 | 16.76M |
| September 16, 2024 | 20.15M |
| September 13, 2024 | 33.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-197.65M
Minimum
Nov 13 2023
1.735B
Maximum
Nov 05 2021
533.46M
Average
615.74M
Median
Aug 18 2020
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
| Oragenics Inc | 2.273M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.66M |
| Revenue (Quarterly) | 17.97M |
| Total Expenses (Quarterly) | 42.16M |
| EPS Diluted (Quarterly) | -1.07 |
| Profit Margin (Quarterly) | -126.1% |
| Earnings Yield | -58.54% |
| Normalized Earnings Yield | -58.54 |